A030007L17Rik Activators represents a class of chemical compounds that can enhance the activity of the A030007L17Rik gene. The initial stage in the identification of such activators involves high-throughput screening (HTS). This approach is pivotal for sifting through large libraries of chemicals to pinpoint those with the desired effect on gene activity. Specifically, in this context, a reporter gene assay is set up where the A030007L17Rik promoter controls the expression of a detectable reporter gene. The reporter gene typically encodes for a protein capable of generating a measurable signal, such as fluorescence or luminescence, upon activation. When various chemical compounds are introduced to this system, those that can upregulate the promoter's activity will yield a higher reporter signal. Compounds that produce a significant elevation in reporter activity are flagged as potential activators of the A030007L17Rik gene. These candidate molecules are earmarked for further confirmatory studies to validate their gene-activating potential.
After the high-throughput screening identifies promising compounds, the next step involves validation using quantitative PCR (qPCR). This technique is employed to accurately quantify the expression levels of the A030007L17Rik mRNA in the presence of the chemical activators. An increase in mRNA levels would suggest that the chemical can activate the gene at the transcriptional level. To ensure that this increase in mRNA results in a corresponding increase in protein expression, Western blot analysis is then carried out. This involves resolving cellular proteins by gel electrophoresis, transferring them onto a membrane, and then probing with antibodies that are specific to the A030007L17Rik protein. A visible enhancement in the detected protein levels, in comparison to untreated controls, would confirm the compound's efficacy in activating the gene, indicating a successful upregulation of the protein product. These methods together provide a robust confirmation of the chemical's role as an activator, establishing a direct link between the observed gene activation at the mRNA level and the ultimate production of the protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is an activator of protein kinase C (PKC). PKC phosphorylates serine and threonine residues on many target proteins. If “A030007L17Rik” is part of a pathway that is regulated by PKC or has serine/threonine phosphorylation sites, PMA could enhance its functional activity through this mechanism. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Calcium is a second messenger in many signaling pathways and can activate calcium-dependent kinases such as calmodulin-dependent kinase (CaMK). If “A030007L17Rik” is activated by CaMK or is part of calcium-regulated pathways, ionomycin could enhance its activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is known to inhibit certain types of kinases. If “A030007L17Rik” is negatively regulated by a kinase that EGCG inhibits, the inhibition of that kinase could lead to an indirect increase in “A030007L17Rik” activity by removing inhibitory phosphorylation. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase-3 (GSK-3). Inhibition of GSK-3 could lead to activation of signaling pathways that involve beta-catenin, among others. If “A030007L17Rik” is part of the Wnt/beta-catenin pathway, lithium could indirectly activate “A030007L17Rik” by inhibiting GSK-3. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A. Inhibition of these phosphatases prevents dephosphorylation of proteins, potentially leading to enhanced phosphorylation statusGiven that "A030007L17Rik" is a placeholder name and there is no direct information available about specific activators or pathways, my response will continue with a logical analysis based on known cellular mechanisms that could potentially interact with or activate a generic protein. | ||||||